CLEVELAND--(BUSINESS WIRE)--This September, cancer biotech company Cleveland Diagnostics, Inc. launches ‘A PSA on PSA.’
Short for ‘A Public Service Announcement on the Prostate-Specific Antigen,’ the campaign is returning for its second year and aims to educate patients, families, and caregivers on the importance of prostate cancer testing. The initiative will kick off on September 1st in observance of Prostate Cancer Awareness Month.
During the month, people are encouraged to download a discussion guide from PSAonPSA.com, which shares questions to ask and other helpful information for patients to bring to their next doctor’s appointment. The resource will help foster more productive conversations between patients and healthcare providers to help better navigate the prostate cancer risk assessment process. For every download, Cleveland Diagnostics will make a donation to ZERO Prostate Cancer to fund research and resources to aid in the fight against the disease. In addition, throughout September, ZERO Prostate Cancer will match donations in celebration of the awareness month.
“We’re excited to bring back our ‘A PSA on PSA’ campaign following a successful launch last year,” shared Arnon Chait, PhD, President and CEO at Cleveland Diagnostics. “The survival rates for prostate cancer are promising if caught early, which is why spreading the word on the importance of early detection is absolutely critical. We’re grateful to have the opportunity to lead such an important initiative in this fight against the disease.”
Prostate cancer remains the second most common cancer in American men, with 1 in every 8 men diagnosed during their lifetime, according to the American Cancer Society. Screening typically starts at age 50, or as early as 40 for those at higher risk and is recommended every two years unless a high PSA level is detected. An elevated PSA typically leads to additional testing, ranging from blood tests to biopsies, with varying levels of invasiveness and accuracy.
Cleveland Diagnostics’ mission is to detect cancer early, when it is most treatable and survivable, through the development of highly accurate diagnostic tests. Its IsoPSA prostate cancer test leverages the power of protein structure to provide greater insight into patients’ elevated PSA levels. The test helps determine if patients’ specimens contain structurally-modified PSA proteins that may have originated in cancer cells. This can be extremely valuable for early cancer detection in many patients while helping to minimize the overdiagnosis and overtreatment of others via biopsies or potentially unnecessary and invasive testing.
IsoPSA is covered by Medicare and is available for clinicians to order directly through Cleveland Diagnostics or Quest Diagnostics. A $75M growth equity financing earlier this year has helped expand patient access to IsoPSA as the company continues its mission of detecting cancer earlier.
For more prostate cancer information, stats, and resources, visit PSAonPSA.com
About Cleveland Diagnostics, Inc.
Cleveland Diagnostics is a breakthrough cancer biotechnology company that is changing the shape of cancer detection. The company has unlocked the diagnostic power of protein structure with its revolutionary IsoClear™ platform that enables novel diagnostics based on a single cancer-specific, protein structure-based assessment using easy to execute tests within the clinical lab setting. Learn more at ClevelandDx.com and IsoPSA.com.
About ZERO Prostate Cancer
ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We’re building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 85 cents of every dollar to research and programs. Learn more at zerocancer.org
